Evidence map›Paper›PMID 29490670›Full record

ArticleRadiation oncology (London, England)2018

Impact of

K Schiller, M Devecka, T Maurer, M Eiber, J Gschwend, M Schwaiger, S E Combs, G Habl

Abstract read
In one paragraph

Article in Radiation oncology (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Randomized Trial of Conventional Versus Conventional Plus Fluciclovine (International journal of radiation oncology, biology, physics · 2022
    Trial
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

K SchillerDepartment of Radiation Oncology, Technical University of Munich (TUM), Munich, Germany. kilian.schiller@mri.tum.de.ORCID http://orcid.org/0000-0001-9371-0391
M DeveckaDepartment of Radiation Oncology, Technical University of Munich (TUM), Munich, Germany.
T MaurerDepartment of Urology, Technical University Munich (TUM), Munich, Germany.
M EiberDepartment of Nuclear Medicine, Technical University Munich (TUM), Munich, Germany.
J GschwendDepartment of Urology, Technical University Munich (TUM), Munich, Germany.
M SchwaigerDepartment of Nuclear Medicine, Technical University Munich (TUM), Munich, Germany.
S E CombsDepartment of Radiation Oncology, Technical University of Munich (TUM), Munich, Germany.
G HablDepartment of Radiation Oncology, Technical University of Munich (TUM), Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

methods25 out of 159 patients with primary PC who underwent

results81 (64.3%) of 126 LNs were covered by the CTV with a complete coverage of all positive LNs inside the respective radiation volume in 11 of 25 patients (44%). LNs that were not covered by the CTV included (para-aortic,) common-iliac, pre-sacral, obturatoric, para-rectal, para-vesical and pre-acetabular locations. In a statistical analysis neither the Gleason score, nor the PSA value, nor the calculated risk with the Roach formula correlated with LNs being inside or outside of the CTV in this patient group.

conclusion

Indexed as

AgedAged, 80 and overEdetic AcidGallium IsotopesGallium RadioisotopesHumansLymphatic MetastasisMaleMiddle AgedOligopeptidesPositron Emission Tomography Computed TomographyProstatic NeoplasmsRadiation OncologyRadiotherapy Planning, Computer-AssistedEdetic Acidgallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesOligopeptides

Identifiers

PMID29490670
PMCPMC5831712

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.